At UHN, we strive to deliver Compassionate Care & Caring. Learn more about the services and supports that are available to you throughout your journey.
Our UHN programs and services are among the most advanced in the world. We have grouped our physicians,
staff, services and resources into 10 medical programs to meet the needs of our patients and help us make
the most of our resources.
At the heart of everything we do at UHN are our Healthcare Professionals. Refer a patient to one of our 12 medical programs. Learn more about the resources and opportunities available for professional growth.
University Health Network has grown to be one of the largest research and teaching hospital networks in Canada - pioneers in improving the lives of patients. Our long history of health professions education at Toronto General, Toronto Western, Princess Margaret and Toronto Rehab hospitals has consistently advanced the science of education.
University Health Network is a health care and medical research organization in
Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international
source for discovery, education and patient care.
Being touched by illness affects us in different ways. Many people want to give back to the community
and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one
of our experts for an interview. It's also the place to find UHN media policies and catch up on our news stories, videos, media releases,
podcasts and more.
A team of researchers at Princess Margaret Cancer Centre has identified a way to predict the likelihood of complications in patients undergoing stem cell transplants.
"By digging deeper into the status of certain cells within the immune system, our findings reveal a new strategy to identify individuals at high risk for complications – opening the door to better, more targeted therapies," says the first author of the study, Dr. Omnia Elebyary, who is a graduate student at the cancer centre and the Faculty of Dentistry at the University of Toronto (U of T).
The type of transplant that the research team focused on is called an allogeneic hematopoietic stem cell transplant. It is carried out after chemotherapy or radiation treatment, involves infusing donor blood cells into the patient in hopes of creating a new immune system that can attack and kill any existing cancer cells.
Blood infections are the most common complication for this procedure.
"The presence of an immune cell known as a polymorphonuclear neutrophil has previously been used to monitor the risk of bloodstream infections for patients receiving this type of transplant," says Dr. Michael Glogauer, a clinician investigator at the cancer centre and senior author of the study. "However, little is known about whether the specific functions of these cells or their respective proportions in the bloodstream might provide deeper insights."
The results, published in the
Journal of Clinical Infectious Diseases, reveal that measuring the proportion of polymorphonuclear neutrophils (PMNs) in a "primed" state after transplant could serve as a powerful tool to identify those at risk.
Immune cells become pre-activated or "primed" when they come in contact with a foreign substance in the body – such as bacteria or viruses. Once they are in this state they are ready to fight off the invader.
The researchers analyzed blood and saliva samples from 76 patients receiving this transplant. They used the proportion of primed PMNs in the blood five days after the procedure to determine which patients fell into high and low PMN groups.
Patients with more than 10 per cent of their PMNs in the primed state were considered to have high levels. Patients in the low group were more susceptible to infections.
"These findings highlight the potential clinical value of this white blood cell subset in identifying patients at higher risk of bloodstream infections," adds Dr. Glogauer, who is also Interim Head of the Department of Dental Oncology, Ocular and Maxillofacial Prosthetics at the Princess Margaret and a professor in the Faculty of Dentistry at U of T. "This could be particularly important in patients undergoing chemotherapy and in those with bone marrow disorders."
This work was supported by Friends for Life and The Princess Margaret Cancer Foundation.